Rallybio Corp cotiza a 16.72 USD y tiene una capitalización bursátil de $89M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of compleme…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.85 | $-1.46 | $-1.52 | $2.88 |
| Estimado | $-1.28 | $-1.20 | $-1.17 | $-1.56 |
| Sorpresa | +33.6% | -21.7% | -29.9% | +284.6% |
| Métrica | RLYB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -3853.6% | -38.6% | -3815.0% |
| Net Margin | -1046.4% | -33.6% | -1012.8% |
| FCF Margin | — | -13.9% | — |
| ROE | -15.5% | -40.4% | +24.9% |
| ROA | -14.4% | -32.0% | +17.6% |
| Current Ratio | 14.50 | 2.84 | +11.66 |
| Debt / Equity | — | 0.28 | — |